Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Welspun Syntex Ltd

    Welspun Syntex now known as AYM Syntex was started in 1972 is now, the largest exporter of texturized polyester yarn from India. Its plants are located in Silvassa from there

  • No Image
    Yashica Pharmaceuticals Pvt Ltd

    Yashica Pharmaceutical was established in year 2007 under the vision of Mr.Sanjay Totre. They have global presence is in more than 20 countries. As an integrated healthcare solu